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ABSTRACT
The accuracy and performance of four automated
instruments (BD Phoenix, MicroScan WalkAway,
VITEK-2 and Wider) were evaluated for suscep-
tibility testing of ﬂuoroquinolones and b-lactams
with four clinical isolates of Klebsiella pneumoniae
and the corresponding Escherichia coli transconju-
gants containing a plasmid carrying the qnr gene
and coding for FOX-5 production. No major or
very major errors were detected with the Micro-
Scan system. Many of the minor errors for both
quinolones and b-lactams clustered around the
intermediate breakpoints.
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Resistance to ﬂuoroquinolones is increasing in
many bacteria of clinical importance [1]. Mecha-
nisms of ﬂuoroquinolone resistance in Gram-
negative bacteria include mutations in genetic
loci such as gyrA, parC, gyrB and parE [2].
Changes in the expression of efﬂux pumps and
porins may also contribute to ﬂuoroquinolone
resistance [3]. Recently, a new mechanism, plas-
mid-mediated quinolone resistance, has been
described [4]. The responsible gene is qnr, which
itself confers only a low level of resistance, but
which may contribute to clinical resistance when
associated with other mechanism(s). Problems in
the use of automated systems to detect ﬂuoroqu-
inolone resistance have been reported, although
corrective action by equipment manufacturers
appears to have resolved these problems [5].
However, the accuracy of these systems has not
yet been assessed with organisms expressing the
qnr gene.
Plasmids carrying the qnr gene usually also
carry genes coding for b-lactamases, most fre-
quently the AmpC-type enzyme FOX-5 [6,7]. The
purpose of the present study was to evaluate the
performance of four automated instruments,
namely the BD Phoenix (BD Diagnostic Systems,
Sparks, MD, USA), MicroScan WalkAway (Dade
Behring, West Sacramento, CA, USA), VITEK-2
(bioMe´rieux-Vitek, Hazelwood, MO, USA) and
Wider (Francisco Soria Melguizo S.A., Madrid,
Spain) systems, for susceptibility testing of ﬂuor-
oquinolones and b-lactams with four clinical
isolates of Klebsiella pneumoniae and their corres-
ponding Escherichia coli transconjugants. The
latter contained a plasmid coding for both Qnr
and FOX-5 production [4,8], but only FOX-5-
expressing transconjugants were obtained from
one K. pneumoniae isolate (1132) because, for
unknown reasons, none of the E. coli transconju-
gants obtained with this donor strain were able to
express FOX-5 and Qnr simultaneously.
The NCCLS broth microdilution assay [9] was
used as the reference test method for the follow-
ing antibiotics: ampicillin (Sigma, Madrid, Spain);
cefotaxime (Sigma); cefoxitin (Sigma); ceftazidime
(Glaxo, Barcelona, Spain); ciproﬂoxacin (Bayer,
Leverkusen, Germany); nalidixic acid (Sigma);
norﬂoxacin (Sigma); and oﬂoxacin (Roussel Uclaf,
Romainville, France). For susceptibility testing
using the automated systems, inocula were pre-
pared according to the manufacturers’ suggested
procedures. The card and panels used in this
study were as follows (mg ⁄L): NMIC ⁄ ID-12
Combo panel for the BD Phoenix (ampicillin,
4–16; cefotaxime, 1–16; cefoxitin, 4–16; ceftazi-
dime, 1–16; ciproﬂoxacin, 0.125–2; nalidixic acid,
8–32; and norﬂoxacin, 2–8); Combo Negative type
1S panel for MicroScan WalkAway 96 (ampicillin,
4–16; cefotaxime, 0.5–32; cefoxitin, 8–16; ceftazi-
dime, 1–16; ciproﬂoxacin, 0.12–2; and oﬂoxacin,
0.5–4); Gram-negative MIC panel for Wider
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(cefoxitin, 4–16; ceftazidime, 0.5–16; ciproﬂoxacin,
0.12–4; and nalidixic acid, 4–16); and AST-N020
for VITEK-2 (ampicillin, 4–32; cefotaxime, 1–32;
cefoxitin, 8–32; ceftazidime, 1–32; ciproﬂoxacin,
0.5–4; oﬂoxacin, 0.5–4; and norﬂoxacin, 1–32). The
MICs obtained were interpreted as susceptible,
intermediate or resistant according to NCCLS
criteria [9]. ‘Very major errors’ were recorded
when an organism was considered resistant by
the reference method, but susceptible by the test
method. ‘Major errors’ were recorded when an
organism considered susceptible by the reference
method was resistant by the test method. ‘Minor
errors’ were recorded when an organism was
considered susceptible or resistant either by the
reference or the test method, but intermediate by
the other method. All tests showing very major
errors or major errors were repeated in duplicate
by both test and reference methods. MICs of
quinolones and b-lactams obtained by the refer-
ence method and the four automated systems are
shown in Table 1. The number of errors for
quinolones and b-lactams by the test method
when compared with the reference method are
shown in Table 2.
For quinolones, very major errors were
observed only for nalidixic acid, norﬂoxacin and
oﬂoxacin. The very major errors for nalidixic acid
were produced by the BD Phoenix and Wider
systems (the MicroScan panels and the VITEK-2
cards do not contain this antimicrobial agent). The
MIC of nalidixic acid for the strains involved in
very major errors was 32 mg ⁄L (close to the
intermediate breakpoint), while the MIC obtained
with the automated systems was 16 mg ⁄L (except
for strain KpN5, for which the MIC with the BD
Phoenix system was 8 mg ⁄L). The very major
errors observed for norﬂoxacin and oﬂoxacin
were produced by the VITEK-2 system with
strain UAB1. Major errors were only observed
for ciproﬂoxacin with the BD Phoenix and Wider
systems for strain 1960. The MIC for this strain
was consistently > 2 mg ⁄L by BD Phoenix and
4 mg ⁄L by Wider, but was 1 mg ⁄L by the refer-
ence method. Minor errors were encountered in
all the systems evaluated. The number of minor
errors was higher for ciproﬂoxacin than for the
other quinolones. Overall, MicroScan appeared to
be the best system for testing susceptibility to
quinolones.
For b-lactams, no errors were found for cefox-
itin and ampicillin. Very major errors were found
only for ceftazidime with the BD Phoenix and
Wider systems. The MIC of ceftazidime for UAB1
TC (the strain responsible for the very major
errors) was 32 mg ⁄L (close to the intermediate
breakpoint), while the MIC obtained with the
automated systems was 8 mg ⁄L. The only major
Table 1. Comparison of MICs (mg ⁄L) obtained by the








UAB1 Ciproﬂoxacin 2 2 > 2 2 1
Nalidixic acid 32 NT > 32 16 NT
Norﬂoxacin 16 NT > 8 NT 2
Oﬂoxacin 16 4 NT NT 2
Cefoxitin > 128 > 16 > 16 > 16 > 64
Ceftazidime 64 > 16 > 16 > 16 16
Cefotaxime 8 8 16 8 4
Ampicillin > 128 > 16 > 16 NT > 32
KpN5 Ciproﬂoxacin 0.25 1 1 2 0.25
Nalidixic acid 32 NT 8 16 NT
Norﬂoxacin 2 NT 2 NT 0.5
Oﬂoxacin 2 2 NT NT 2
Cefoxitin 128 > 16 > 16 > 16 > 64
Ceftazidime 32 > 16 > 16 16 16
Cefotaxime 8 32 > 16 8 4
Ampicillin > 128 > 16 > 16 NT > 32
1960 Ciproﬂoxacin 1 1 > 2 4 2
Nalidixic acid > 256 NT > 32 > 16 NT
Norﬂoxacin 4 NT 8 NT 8
Oﬂoxacin 4 > 4 NT NT > 8
Cefoxitin 256 > 16 > 16 > 16 > 64
Ceftazidime 16 16 > 16 > 16 16
Cefotaxime 4 4 8 4 4
Ampicillin > 128 > 16 > 16 NT > 32
1132 Ciproﬂoxacin 4 > 2 > 2 4 > 4
Nalidixic acid > 256 NT > 32 > 16 NT
Norﬂoxacin 16 NT > 8 NT 16
Oﬂoxacin 16 > 4 NT NT > 8
Cefoxitin > 256 > 16 > 16 > 16 > 64
Ceftazidime 64 > 16 > 16 > 16 > 64
Cefotaxime 8 8 16 8 8
Ampicillin > 128 > 16 > 16 NT > 32
UAB1 TC Ciproﬂoxacin 0.5 1 0.5 2 1
Nalidixic acid 32 NT 16 16 NT
Norﬂoxacin 2 NT 2 2 NT
Oﬂoxacin 1 2 NT NT 2
Cefoxitin > 128 > 16 > 16 > 16 > 64
Ceftazidime 32 > 16 8 8 16
Cefotaxime 8 8 8 8 4
Ampicillin > 128 > 16 > 16 NT > 32
KpN5 TC Ciproﬂoxacin 0.125 1 0.25 2 < 0.25
Nalidixic acid 32 NT 16 16 NT
Norﬂoxacin 1 NT 2 2 NT
Oﬂoxacin 0.5 2 NT NT 2
Cefoxitin 32 > 16 > 16 > 16 > 64
Ceftazidime 8 16 16 16 16
Cefotaxime 2 4 8 4 4
Ampicillin > 128 > 16 > 16 NT > 32
1960 TC Ciproﬂoxacin 0.125 1 0.25 2 < 0.25
Nalidixic acid 32 NT 16 16 NT
Norﬂoxacin 1 NT 2 2 NT
Oﬂoxacin 0.5 2 NT NT 1
Cefoxitin 32 > 16 > 16 > 16 > 64
Ceftazidime 8 8 8 8 16
Cefotaxime 2 4 8 8 4
Ampicillin > 128 > 16 > 16 NT > 32
1132 TC Ciproﬂoxacin 0.008 < 0.12 < 0.13 < 0.12 < 0.25
Nalidixic acid 4 NT < 8 < 4 NT
Norﬂoxacin 0.06 NT < 2 < 0.5 NT
Oﬂoxacin 0.06 < 0.5 NT NT < 0.25
Cefoxitin 128 > 16 > 16 > 16 > 64
Ceftazidime 32 16 16 16 16
Cefotaxime 4 8 8 8 4
Ampicillin > 128 > 16 > 16 NT > 32
NT, not tested; TC, Escherichia coli transconjugant.
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error was observed for cefotaxime and the BD
Phoenix system with strain KpN5. The MIC for
this strain was consistently > 16 mg ⁄L with the
BD Phoenix system, but was 8 mg ⁄L with the
reference method. Minor errors were detected
only for susceptibility testing of ceftazidime and
cefotaxime.
It is noteworthy that the BD Phoenix drew
attention to the possibility of extended-spectrum
b-lactamase production by all of the strains tested,
and, in the case of VITEK-2, a recommendation
was made about changing the clinical category of
all the cephalosporins to the resistant range.
Plasmid-encoded AmpC b-lactamases are found
increasingly among isolates of K. pneumoniae and
E. coli. There is no NCCLS recommendation
regarding the MIC interpretation or detection of
K. pneumoniae isolates producing this type of
b-lactamase, but it seems reasonable that they
should be considered resistant to all b-lactams,
with the exception of carbapenems and, probably,
zwitterionic cephalosporins.
Many of the minor errors for both quinolones
and b-lactams clustered around the intermediate
breakpoints. Thus, a change in the MIC for an
organism by ± 1 doubling dilution often resulted
in a minor error. The panels or cards of these
automated systems contain a limited number of
wells for susceptibility determination. For this
reason, in addition to the fact that the intermedi-
ate range for antimicrobial agents consists of a
single dilution, an error in just one well could
cause an inaccurate result. If errors within one
dilution of the broth microdilution reference
method were excluded from analysis, most minor
errors would be eliminated, including the very
major errors in the case of nalidixic acid, for
which intermediate susceptibility does not exist.
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Table 2. Quinolone and b-lactam susceptibility testing
errors observed with the automated systems, compared
to results obtained by the reference microdilution method
Drug Errors MicroScan BD Phoenix Wider VITEK-2
Ciproﬂoxacin Minor 0 1 4 2
Major 0 1 1 0
Very major 0 0 0 0
Nalidixic acid Minor – 0 0 –
Major – 0 0 –
Very major – 4 5 –
Norﬂoxacin Minor – 1 – 1
Major – 0 – 0
Very major – 0 – 1
Oﬂoxacin Minor 2 – – 1
Major 0 – – 0
Very major 0 – – 1
Cefoxitin Minor 0 0 0 0
Major 0 0 0 0
Very major 0 0 0 0
Ceftazidime Minor 2 3 4 6
Major 0 0 0 0
Very major 0 1 1 0
Cefotaxime Minor 1 2 0 0
Major 0 1 0 0
Very major 0 0 0 0
Ampicillin Minor 0 0 – 0
Major 0 0 – 0
Very major 0 0 – 0
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